Forbes

Think you need a testosterone checked? A physician explains what symptoms should prompt testosterone screening, how to interpret results, and when to consider treatment.

Most AI drug development firms are focused on discovery. AI biotech Formation Bio is betting the real bottleneck is clinical trials. With a new $600 million fund to buy or license potential drugs that have stalled out, the startup now hopes to prove that it’s right.

A doctor writes a guide to the seven health issues voters care about most in the 2026 midterms, from health costs and ACA premiums to Medicaid, fraud and abortion.

At Health Datapalooza, patient advocates explore how healthcare can move beyond a seat at the table to recognize expertise and give patients meaningful influence.

Mike Collette’s CFO said PatientPoint was three weeks from shutdown. Here’s how he built a point-of-care giant and later bought the rival that fooled investors.

Drug developers have designed therapies to reduce the cholesterol-carrying molecule Lp(a), which is associated with heart disease, but a trial has left experts stumped.

Reese’s Peanut Butter Cups rank among America's top Halloween treats, raising questions about peanut allergy safety during trick-or-treating.

CiCi McMullen bought HerScan, which brings supplemental breast ultrasound to women in 48 states. McMullen was the only female bidder and pitched 60 investors to fund it.

Centene reported a $71 million third quarter loss though much improved over the year-ago period as the health insurer gets a handle on costs dogging the industry.

Palantir cofounder Joe Lonsdale is investing in an animal testing company that aims to secure a national supply chain of monkeys for biomedical testing.

Addressing America's $5.7 trillion healthcare spending crisis takes more than candidates promising relief. It requires congressional action through two promising paths.

"Maxxing" is Dicitionary.com's 2026 Word of the Year because there have been so many different "maxxing" trends on social media like "looksmaxxing" and "fibermaxxing."

The company indicated significant success with its initial roll-out earlier this year, and is now looking to expand its agentic reach.